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Dexamethasone, Prostaglandin A, and Retinoic Acid Modulation of
Murine and Human Melanoma Cells Grown in Soft Agar1,2,3
Marvin D. Bregman,4 Elizabeth Peters," Diane Sander,4 and Frank L. Meyskens, Jr. 4,5
ABSTRACT-The cloning efficiencies of a murine melanoma cell line
(S91 CCl 53.1) and a human melanoma cell strain (C8146c) were
inhibited by dexamethasone (DEX), prostaglandin A1 (PGA1) , and {3-aIl-
trans-retinoic acid (RA) in a dose-dependent manner. Murine melanoma
tumor colony-forming units (MTCFU) were inhibited more than 99% by
DEX (1xt 0- 7 M) and RA (1xt 0- 7 M) with a concentration needed to
produce a 50% reduction in colony formation for both hormones of
5X10-9 M. Combinations of DEX and RA effected a synergistic inhibition
on colony formation, which was reflected by a 1V2 log reduction in the
hormone concentration needed to produce a greater than 99% inhibition
of colony formation. When PGA1 was added to DEX and RA, a greater
than additive reduction in colony formation was observed. Human
MTCFU from cell strain C8146c were inhibited more than 85% at an RA
concentration of 1xt 0- 7 M, but they were reduced only to 40% of control
at a DEX concentration of 1x10-6 M. DEX-RA produced an additive
inhibition of colony formation. Addition of submaximal amounts of PGA1
to DEX-RA combinations or to either hormone alone resulted in syner-
gistic reduction of human MTCFU. These results demonstrated that the
proliferative potential of human and murine melanomas can be simulta-
neously regulated by DEX, PGA1 , and RA.-JNCI1983; 71:927-932.
Several hormones including steroids, retinoids, and
prostaglandins inhibit melanoma cell proliferation and/
or induce differentiation (1-8). Glucocorticoids inhibit
the proliferation of hamster melanoma cells (4) and
induce differentiation in murine melanoma cells as mea-
sured by changes in tyrosinase activity (3). The inability
of glucocorticoids to produce complete regressions of
melanomas in vivo may be due to resistant mutants, as
suggested by a recent study in which nonresponsive
clones were isolated from a glucocorticoid-sensitive mel-
anoma cell line (4). The high incidence of glucocorticoid
receptors in cells from biopsy samples obtained from
patients with melanoma suggests that human melanoma
cells may also be responsive to this hormone (9).
Retinoids inhibit the proliferation and induce differ-
entiation of murine melanoma cells in vitro (1, 10). Some
human melanoma cells in culture are inhibited by RA,
but the response is not uniform, with the growth of some
cell lines being either insensitive to or even stimulated
by RA (11). Even clones selected from individual human
(12) and murine (13) melanoma cell lines displayed dif-
ferential sensitivities to RA. We have found that cells
from biopsy specimens of melanoma tissue grown in agar
also demonstrated marked heterogeneity in response
from patient to patient, ranging from a substantial inhi-
bition of melanoma colony formation to no effect (14).
Prostaglandins also inhibit the growth of murine mel-
anoma tumors in vivo (15, 16). PGA I is a strong inhibitor
of DNA synthesis (6, 17), and we have found the growth
of murine melanoma cells in soft agar to be strongly
inhibited by PGA I (7). Turner et al. (18) recently re-
ported that irreversible inhibition of murine melanoma
growth occurs only if the cells are exposed continuously
to PGA I for more than 72 hours. Our laboratory has
also found that PGA I is a potent inhibitor of human
melanoma colony formation and that prostaglandins B I ,
FlO', and F2a were inactive (19).
Previous studies have measured the activity of a single
hormone such as DEX or retinoids on melanoma cell
growth. The use of antiproliferative hormones in com-
bination may lead to an enhanced biological response.
In this communication we measured the combined ef-
fects of DEX, RA, and PGA I on human and murine
clonogenic tumor cells in vitro. The reduction of
MTCFU in soft agar was enhanced by continuous ex-
posure to the combined hormones.
MATERIALS AND METHODS
Chemirols.-DEX and RA were purchased from Sigma
Chemical Co., St. Louis, Mo. Ham's F-I0 medium was
obtained from GIBCO, Santa Clara, Calif. FCS and HS
were from KC Biological, Lenexa, Kans. PGA I was ob-
tained from The Upjohn Co., Kalamazoo, Mich.
Cell rultures.-The Cloudman S91 murine melanoma
clone CCL 53.1 was obtained from the American Type
Culture Collection, Rockville, Md., and was maintained
by serial transplantation in DBA/2] mice. The tumors
were harvested, and single-cell suspensions were ob-
tained as previously described (7). The cells were added
to a flask containing F-I0 media with 10% HS and 2%
FCS. CCL 53.1 cells readily formed a monolayer and
were subsequently subcultured. All experiments were
performed on cells that had been subcultured no more
than 10 times after isolation from mouse melanomas.
ABBREVIATIONS USED: DEX-dexamethasone; FCS=fetal calf serum
(heat-inactivated); HS=horse serum; ID 50=concentration needed to
produce a 50% reduction in melanoma colony formation; MTCFU=
melanoma tumor colony-forming units; PGAI=prostaglandin AI;
RA={3-all-tralls-retinoic acid.
I Received January 18, 1983; accepted June 21, 1983.
2 Supported in part by grant PDT 184 from the American Cancer
Society and by Public Health Service grants CA-27502 and CA-17094
from the National Cancer Institute.
3 Research procedures were according to the ethical standards of the
Human Studies Committee, University of Arizona.
4 Department of Internal Medicine and Cancer Center, Arizona
Health Sciences Center, University of Arizona, 1501 North Campbell
Ave., Tucson, Ariz. 85724.
5We thank R. Markmann and L. Kimball for preparation of the
manuscript and the graphics.
927 JNCI, VOL. 71, NO.5, NOVEMBER 1983
928 Bregman, Peters, Sander, and Meyskens
The human melanoma cell strain C8146c was developed
in our laboratory from cells obtained from biopsies of
subcutaneous nodules and is described in detail else-
where (19). Early subcultures of C8146c were stored in
the vapor phase of liquid nitrogen. C8146c was grown
in Ham's F-I0 medium containing 10% FCS and was not
used for more than 10 subculturings. C8146c has tyro-
sinase activity (19), and the cells grown in agar contain
melanosomes (Hendrix M: Personal communication). In
culture the doubling time of C8146c was 51 hours.
These human melanoma cells when implanted in nude
mice generated tumors within 6 weeks.
Clonogenic assay.-The assay system is a simplification
of the bilayer agar assay developed by Salmon and co-
workers (20, 21), as we have previously described (22).
A bilayer of agar in medium without additional additives
was constructed in 35-mm-diameter petri dishes. For
human melanoma cell lines the medium used in both
agar layers was Ham's F-I0 with 10% FCS, and 10,000-
20,000 cells were plated per dish. The murine cell line
was plated at a concentration of 5,000 cells/ml in Ham's
F-I0 medium containing 10% HS and 2% FCS. The
petri dishes were incubated at 37°C in a humidified
atmosphere containing 6% CO2 for 10-14 days. The
colonies were counted and grouped into size classes
based on colony diameter with the use of an optical
image analyzer (Omnicon FAS II; Bausch & Lomb,
Rochester, N.Y.) (23). The colony size cutoff was arbi-
trarily chosen as 60 um, which corresponded to 28 cells
for CCL 53.1 on day 10 and 10 cells for C8146c on day
14. 6 PGA 1 , DEX, and RA were added at various concen-
trations with the cells on day O. The experiments were
done in the dark, and all stock solutions were protected
from light with a foil wrap.
Data analysis.-Cloning efficiencies were calculated
from the total number of cells plated. Visual inspection
of the dishes through a microscope on day 0 found the
top agar layer contained only single cells. The in vitro
hormone effects in the combination studies were quan-
titated according to the methods of Valeriote and Lin
(24) and Drewinko et al. (25). The surviving fraction
(5'F) of MTCFU resulting from each hormone individ-
ually and the surviving fraction of the hormone combi-
nation were determined experimentally. If the SFA + B
was equal to (SFA.) · (SFB), the combined drug effects were
additive. If the SF.4+B was less than (SFA)·(SFB), the
combined effect was defined as greater than additive or
synergistic. If the SF,,;, + Bwas greater than (SF,,;,). (SFB) but
less than (SF,,;,) and (SFB), the combination interaction
was defined as subadditive. If the SF,,;, +B was greater than
(SF,,;,)' (SFB) and greater than or equal to the lowest value
SF,,;, or SFB, the combination interaction was defined as
antagonistic (26). Statistical comparisons between the
experimental and calculated data were done for each of
the hormones.
For each combination of hormones, the difference for
6The number of cells per colony size was derived either by compu-
tation or exact measurement (Meyskens FL Jr, Thomson SP, Moon
TE: Unpublished observations).
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the observed minus expected percentage survivals of
MTCFU was calculated for each experiment. The z-
statistic calculated for the hormone combination is the
difference (observed minus expected) of MTCFU sur-
vival divided by the square root of the observed v.aria.nce
of the surviving fraction for the hormone combination,
yielding a standard normal z-statistic with cor~esponding
P-values according to the method of Drewmko et al.
(25). With the use of this approach, drugs that produce
a perfectly additive response give a z-value of O. We have
designated a P-value of .05 or less as indicating an
antagonistic or synergistic effect of the combination (de-
pending on the direction of the z-value) and a P-value of
greater than .05 but less than .20 as indicating a subad-
ditive or subsynergistic response.
RESULTS
Effect of DEX and RA on Melanoma Colony Formation
CCL 53.1 murine melanoma cell growth in soft agar
was sensitive to RA in a dose-dependent fashion (text-
fig. 1). The m., of RA was 5x 10-9 1\1 (table 1). A
greater than 95% reduction i~ colony form
7ation
w~s
achieved at an RA concentration of 1X 10- 1\1. ThIS
murine cell line responded in a like manner to DEX with
an ID so occurring at 5x 10-9 A1. The inhibition of colony
formation by DEX was dose-dependent with more than
95% inhibition occurring at a concentration of 1X 10-7
i\1.
The sensitivity of human melanoma cells of strain
C8146c to RA (text-fig. 1) was comparable to the re-
sponse obtained with the murine melanoma cell line. An
RA concentration of sx10-91\1 produced a 50% reduc-
tion in MTCFU, and a greater than 85% inhibition was
obtained at a concentration of 1X 10-7 M (table 1). When
the treated cells were grown for an additional 5 days,
the remaining colonies were larger, but no additional
colonies appeared. Thus reduction in colony number
effected by RA was not due to an increase in doubling
time but due to a total inhibition of growth. The human
melanoma cells were not as sensitive to DEX as the
murine cells. A 50% reduction in MTCFU was achieved
with a DEX concentration of sx1O-R M. This concentra-
tion was a log higher than that needed to produce a 50%
reduction in MTCFU from the murine line. A complete
reduction in MTCFU from C8146c could not be
achieved at an):' concentration tested. DEX concentra-
tions of 1X 10-7 to 1X 10-6 M resulted in only a 60%
reduction in colony formation (table 1), demonstrating
that a large portion of the MTCFU from C8146c was
insensitive to this hormone.
Effect of DEX and RA in Combination on Melanoma
Colony Formation
When both RA and DEX were added to murine mel-
anoma cells in soft agar at nanomolar concentrations,
there was a synergistic inhibition of the number of ~ol­
onies formed (table 2). For example, at a concentration
of 1X 1O-~ 1\1, DEX and RA reduced MTCFU 8 and
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TEXT-FIGURE I.-Effect of increasing concentrations of
DEX (.t,.----.t,.) and RA (0--0) on the anchorage-inde-
pendent growth of CCL 53.1 (panel A) and increasing
concentrations of DEX (.t,.---.t,.) and RA (0--0) on
C8146c (panel B). Control plates were seeded with
5,000 CCL 53.1 and 15,000 C8146c cells and con-
tained 2,750±56 and 2,676±86 colonies, respectively.
The experiments were repeated two more times, and





























HORMONE II 10-9 M
18%, respectively. The expected inhibition was 25%;
however, the observed reduction in MTCFU was much
greater than additive (table 2). This synergism occurred
in a dose-dependent manner between the concentration
range of 1-10 wU. When RA and DEX were used
together, the ID so was slightly greater than 1X 10-9 M.
This was a half-log decrease over the concentration
needed when either DEX or RA was added alone. Also,
when RA and DEX were added simultaneously, there
was a decrease of 1-11/2 logs over the concentration
needed for each hormone alone to elicit greater than
98% inhibition (table 2).
TABLE I.-Hormone sensitivity of established murine (CCL 53.1) and
human (C8146c) melanoma cells in soft agar
The data in table 2 show that DEX and RA can act
together to inhibit the MTCFU from the human mela-
noma cell strain C8146c. An additive reduction in
MTCFU was obtained with all concentrations up to
1X 10-8 M. The sensitivity of these human melanoma
cells to the combined action of DEX-RA was not as
dramatic as those inhibitions seen with the murine cell
line. DEX-RA at 5x 10-9 1\1 effected a significant 70%
reduction in colony number. Only 60% of the MTCFU
in this human melanoma cell line were sensitive to DEX
(text-fig. 1). Yet when DEX was added with RA at
5x 10-9 M, a further 40% reduction in colony number
was observed over that obtained with RA alone.
Effect of PGA1 on DEX and RA Inhibition of MTCFU
Maximum inhibition
ofMTCFU
Cell line Treatment ID50, M Percent Concen-
control tration,
M
CCL 53.1a DEX 5xlO-9 3 1XlO- 7
PGA 1 2X10-6 0 7xlO-6
RA 5xlO-9 4 1xlO-7
C8416cb DEX 5XlO-8 40 1XlO-6
PGA 1 2x10-6 0 7xlO-6
RA 5XlO-9 14 1XlO-7
"Single-cell suspensions of CCL 53.1 were plated in quadruplicate
as described in "Materials and Methods." Control plates yielded 3,056±
52 colonies >60 JLm on day 10. Cloning efficiency was 61%.
"Singie-cell suspensions of C8146c were plated in quadruplicate as
described in "Materials and Methods." Control plates yielded 1,640±
56 colonies >60 JLm on day 14. Cloning efficiency was 16%.
We have previously demonstrated that PCA] irrevers-
ibly inhibited the anchorage-independent growth of mu-
rine melanoma (19), but the concentration needed to
produce complete inhibition was very large (7 ,.,,1\1). Be-
cause PCAI may be inhibiting melanoma cell growth
through an as yet undefined biological mechanism, the
effect of lower concentrations in combination with other
hormones was tested. As shown in text-figure 2, submax-
imal concentrations of PCA] resulted in a dramatic de-
crease in murine melanoma colony formation in the
presence of RA and DEX. The observed inhibition curve
was greater than the calculated additive effects (text-fig.
2). DEX-RA used at a low concentration (lxl0-91\1) or
PCAI at a low concentration (l00 ng/ml) produced only
a minor reduction in MTCFU. The addition of PCAI to
JNCI, VOL. 71, NO.5, NOVEMBER 1983
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TABLE 2.-Effect of DEX-RA combination on melanoma colony formation
Percent inhibition" Statistical evaluation
Cell line Treatment (concentration) Observed effect,"Expected
±SE z
p
CCL 53.1 RA-DEX (both 1xlO-9 M) 25 46±1 S -10.5 .0001
RA (lXlO-9 M) + DEX (5X10-9 M) 44 84±1 S -20.0 .0001
RA (lxlO-8 M) + DEX (5x10-9 M) 91 98±0.5 S -7.00 .0001
RA-DEX (both 1 x 10-8 M) 93 100 S 0
C8146c RA-DEX (both 1xlO-9 M) 33 32±1 A 0.50 .61
RA-DEX (both 2.5x10-9 M) 53 53±1 A 0 1
RA-DEX (both 5xlO-9 M) 70 70±2A 0 1
RA (lxlO-8 M) + DEX (5X10-9 M) 75 75±0.5 A 0 1
RA-DEX (both 1xlO-8 M) 78 79±1.5 A -0.33 .73
"The effect of the expected and observed inhibition was calculated as described in "Materials and Methods."
"Results are expressed as standard errors relative to mean of control. A z-value of 0 indicates that the expected and observed survival percentages
of the combination were equal. The larger a positive value, the greater the chance the combination was antagonistic (A). The larger a negative
value, the greater the chance the combination was synergistic (S).
TEXT-FIGURE 2.-Effect of lXl0-9 M DEX and
1X10-9 M RA in combination with increasing
concentrations of PGA) on MTCFU of murine
melanoma CCL 53.1 in soft agar. CCL 53.1
melanoma cells were plated in quadruplicate
as described in "Materials and Methods," and
the hormone(s) were placed in the culture dish.
Control plates had 3, 160±62 colonies >60 JLm.
Colonies >60 JLm contained at least 28 cells,
54% of the colonies were>104 JLm and con-
tained at least 105 cells, and 4% ofthe colonies
were > 149 JLm on day 10 and contained at
least 247 ells. e=PGA alone; o=expected ad-
ditive result ofall three hormones; D=observed
effect of RA plus DEX plus the calculated
effect of PGA); A=DEX and RA plus an in-
creasing concentration of PGA). Point A (-)
shows the reduction in colony formation elic-
ited by the DEX-RA combination. This exper-
iment was done two times, and similar results
were obtained.
















DEX-RA produced an additional 50% reduction of
murine MTCFU.
A similar result was also obtained with the human
melanoma cell line (table 3). The addition of PGA 1
synergistically enhanced the inhibition of MTCFU in the
presence of DEX and RA. A concentration of 100 ng
PGAIfml was very effective in potentiating the inhibitory
effect of 2.5-ruW concentrations of DEX and RA. The
addition of PGA 1 to DEX-RA increased the observed
inhibition in this experiment (table 3) by more than 50%,
which is more than the 11% one would expect for an
additive result. Note that PGA 1 did not enhance the
inhibition in the presence of DEX-RA at 1X 10-9 M.
However, this low dose of DEX-RA did interact syner-
gistically with higher PGA 1 concentrations. The combi-
nation of PGA 1 and DEX or RA also resulted in a
TABLE 3.-PGA 1 effect on human MTCFU inhibition by DEX and RAa
Total colony percent Statistical evaluation Percent inhibi-Treatment (concentration) inhibition ± SE Effect
b tion of colonies,
z p 104 JLIDc
PGA1 (l00 ng/ml) 1l±0.5 1
Plus DEX-RA (both 1XlO-9 M) 33±1 A 7.00 .0001 53
Plus DEX-RA (both 2.5xlO-9 M) 61±1.0 S -8.94 .0001 89
PGA1 (500 ng/rnl) 45±1 41
Plus DEX-RA (both 1xlO-9 M) 79±0.5 S -16.00 .0001 94
Plus DEX-RA (both 2.5xlO-9 M) 81±0.5 S -14.00 .0001 95
PGA1 (l JLg/ml) 75±0.5 87
Plus DEX-RA (both 1XlO-9 M) 92±0.5 S -8.75 .0001 99
Plus DEX (lxlO-7 M) 94±0.5 S -4.28 .0001 99
Plus RA (l X10-8 M) 94±0.5 S -7.14 .0001 99
"Single-cell suspensions of C8146c were plated in soft agar in continuous contact with the compounds as described previously (19).
b A=antagonistic; S=synergistic.
"Total colonies >60 JLm, 2,622, contained at least 10 cells, and 804 colonies were >104 JLm on day 14 and contained at least 36 cells.
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significant increase in the observed inhibition of colony
formation and demonstrated that DEX and RA need not
both be present for PGA 1 to express its synergistic inter-
actions (table 3). For example, the maximal inhibition
effected by DEX at 0.1 pA1 or higher concentrations was
60%. The addition of PGAj, which alone produced a
75% inhibition (table 3), resulted in synergistic interac-
tion, with 94% of the MTCFU being inhibited. Visual
inspection revealed that most of the cells had failed to
divide. There was not a large amount of clusters less
than 60 J.tlW, which one would expect if the hormone
combination was retarding only the growth rate.
DISCUSSION
The growth of melanoma cells from established mu-
rine and human cultures can be strongly inhibited both
in vitro and in vivo by DEX, PGA.. and RA (1, 2, 4-7,
14, 16). However, some melanoma cells are insensitive
to either DEX or RA (4, 11, 13).
The murine melanoma cell line used in this study
represents an ideal case. More than 96% of the colony-
forming cells were totally responsive to single-agent
treatments by DEX or RA. These results are comparable
to those of a previous report in which the dose-depend-
ent effects of RA on the monolayer growth of S91
melanoma were demonstrated (1). The human mela-
noma cell strain represents a more complicated situation.
The colony-forming units were highly responsive to RA,
but a large portion of these cells was resistant to DEX.
The combined use of DEX-RA in murine melanoma
cells resulted in a dramatic reduction of MTCFU expres-
sion. The observed inhibition was much larger than that
predicted for an additive response. The data in table 2
clearly demonstrated that nanomolar combinations of
DEX-RA produced a synergistic inhibition of MTCFU
expression. The enhanced reduction ofcolony formation
may be the result of two processes. The second hormone
could generate an enhanced response by acting on mel-
anoma cells that are resistant to the first hormone, or it
could act in concert with the first hormone at the cellular
level. For example, at a concentration of 1 nM most of
the murine melanoma cells did not respond to either
DEX or RA. Since all the MTCFU can be inhibited by
either hormone alone at reasonable concentrations (table
1), we speculate that the second hormone is not acting
on cells resistant to the first hormone. At 1X 10-9 M a
subthreshold response was generated in most cells by
either DEX or RA. Yet when DEX and RA are added
together, about half of the MTCFU were blocked from
forming colonies. DEX and RA may independently in-
hibit the expression of the same cellular process and
when DEX and RA are combined, the integrated sub-
threshold effects lead to a block in cellular division. It
remains to be elucidated which processes are regulated
either independently or concurrently by these hormones.
The interpretation of the combined DEX-RA effects
on the human melanoma cell strain is more complicated,
since a large proportion of melanoma colony-forming
Hormone Modulation of Melanoma Growth 931
cells did not respond to DEX. If one assumes that DEX
and RA do not work together on the MTCFU to inhibit
colony formation, then the maximal inhibition that could
be achieved would be an additive effect. Since only an
additive effect was observed, one cannot know whether
RA and DEX were acting independently on different
cell populations or if the hormones interacted at the
cellular level to comodulate the human melanoma cells.
At least 60% of the melanoma colony-forming cells were
responsive to both DEX and RA, so the lack of synergism
suggests that the proliferation of human melanoma may
not be as tightly regulated by these hormones in com-
parison to murine melanoma. Nevertheless, the addition
of DEX does contribute to the further suppression of
anchorage-independent growth. For example, at an RA
concentration of 10 nM only 32% of the melanoma
colony-forming cells formed colonies, and the addition
of 10 nM DEX reduced this survival fraction by another
35% (table 2).
In this report we have demonstrated that DEX, RA,
and PGA 1 comodulate melanoma cell growth and pro-
duce a synergistic inhibition of MTCFU expression. For
the combination DEX-RA, these effects were observed
at readily achievable plasma concentrations (27,28). The
other beneficial consequence of using these two hor-
mones in concert is that they lowered the effective inhib-
itory threshold concentration, which is very important
for a solid tumor, inasmuch as the effective concentra-
tion of hormone to which the tumor is expressed may
be much lower than measured plasma levels. The addi-
tive effects of the DEX-RA combination on the MTCFU
of the human melanoma cell strain suggest that the
hormones may be useful in vivo, particularly since a
significant number of cells from fresh biopsy specimens
yielded at least partial inhibitory responses to RA (14).
These results suggest that a subpopulation of patients
may exist with adequate sensitivity to DEX and RA to
allow a significant response to these hormones.
Previous clonogenic assay studies (19) also showed that
PGA 1 can act as a single agent to irreversibly inhibit
melanoma cells, but only at a very high concentration (7
p.Al). In the present study a PGA 1 concentration 25-fold
lower greatly enhanced the inhibitory effects of DEX
and RA. Little is known about the pharmacokinetics of
PGA j in vivo. A preliminary study is under way in which
PGA I has been administered to breast cancer patients
(29). Our data suggest the potential usefulness of PGA1
at this low concentration with DEX and RA. Hopefully,
an analogue of PGA 1 may be developed with a high
therapeutic index for patient studies.
Our observations demonstrate that the clonogenic ca-
pacity of melanoma cells in soft agar is under the control
of several hormones. None of these hormones individ-
ually elicited a major response at useful concentrations,
but in combination and at low concentrations they sub-
stantially inhibited MTCFU. The results presented here
provide a rationale for a multihormone regimen for
advanced melanoma. The coupling of antiproliferative
hormones may also be applicable to other tumor types.
JNCI, VOL. 71, NO.5, NOVEMBER 1983
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